Skip to main content
. Author manuscript; available in PMC: 2022 May 3.
Published in final edited form as: J Control Release. 2020 Dec 21;330:329–340. doi: 10.1016/j.jconrel.2020.12.010

Fig. 8.

Fig. 8.

Efficacy of ECO/pRHO–ABCA4 and ECO/pRHO–ABCA40–SV40 nanoparticles for preventing A2E accumulation in Abca4−/− mice. (A) HPLC analysis of synthesized A2E standard. (B) A2E spectra of synthesized A2E standard, and samples from nanoparticle treated and control mice. (C) HPLC chromatograms of A2E from control, ECO/pRHO–ABCA4, and ECO/pRHO–ABCA40–SV40 nanoparticles treated Abca4−/− mice 8 months after subretinal injections. (D) Quantitative A2E levels of ECO/pRHO–ABCA4 and ECO/pRHO–ABCA40–SV40 nanoparticles treated Abca4−/− mice relative to PBS control mice 8 months after subretinal injections. ABCA4 mRNA expression (E) 4 days and (F) 4.5 months after subretinal treatments of ECO/pRHO–ABCA4 and ECO/pRHO–ABCA4–SV40 nanoparticles in Abca4−/− mice. (error bars = ± SD, **P < 0.05 relative to control eyes. Statistical analysis was conducted with one-way ANOVA).